Nancy Chang, NP

NPI: 1447819388
Total Payments
$24,559
2024 Payments
$627.46
Companies
2
Transactions
11

Payment Breakdown by Category

Research$10,661 (43.4%)
Travel$10,644 (43.3%)
Consulting$2,981 (12.1%)
Food & Beverage$273.12 (1.1%)
Other$0.00 (0.0%)

Payments by Nature

Nature of Payment Amount Transactions Share
Unspecified $10,661 4 43.4%
Travel and Lodging $10,644 3 43.3%
Consulting Fee $2,981 2 12.1%
Food and Beverage $273.12 2 1.1%

Payments by Type

General
$13,898
7 transactions
Research
$10,661
4 transactions

Top Paying Companies

Company Total Records Latest Year
Novo Nordisk AS $24,462 10 $0 (2024)
Medtronic, Inc. $97.46 1 $0 (2024)

Payment History by Year

Year Amount Transactions Top Company
2024 $627.46 2 Novo Nordisk AS ($530.00)
2023 $23,932 9 Novo Nordisk AS ($23,932)

All Payment Transactions

11 individual payment records from CMS Open Payments

Date Company Product Nature Form Amount Type
11/14/2024 Medtronic, Inc. INTELLIS ADAPTIVESTIM (Device) Food and Beverage In-kind items and services $97.46 General
Category: Spinal Cord Neurostimulation
08/23/2024 Novo Nordisk AS Consulting Fee Cash or cash equivalent $530.00 General
01/09/2023 Novo Nordisk AS Rybelsus (Drug) In-kind items and services $10,114.80 Research
Study: NN9924-4437 • Category: Diabetes
01/09/2023 Novo Nordisk AS Rybelsus (Drug) In-kind items and services $313.18 Research
Study: NN9924-4437 • Category: Diabetes
01/09/2023 Novo Nordisk AS Rybelsus (Drug) In-kind items and services $175.66 Research
Study: NN9924-4437 • Category: Diabetes
01/09/2023 Novo Nordisk AS Rybelsus (Drug) In-kind items and services $57.54 Research
Study: NN9924-4437 • Category: Diabetes
01/02/2023 Novo Nordisk AS Rybelsus (Drug) Travel and Lodging In-kind items and services $10,114.80 General
Category: Diabetes
01/02/2023 Novo Nordisk AS Rybelsus (Drug) Consulting Fee Cash or cash equivalent $2,451.25 General
Category: Diabetes
01/02/2023 Novo Nordisk AS Rybelsus (Drug) Travel and Lodging In-kind items and services $313.18 General
Category: Diabetes
01/02/2023 Novo Nordisk AS Rybelsus (Drug) Travel and Lodging In-kind items and services $215.73 General
Category: Diabetes
01/02/2023 Novo Nordisk AS Rybelsus (Drug) Food and Beverage In-kind items and services $175.66 General
Category: Diabetes

Research Studies & Clinical Trials

Study Name Company Amount Records
NN9924-4437 Novo Nordisk AS $10,661 4

About Nancy Chang, NP

Nancy Chang, NP is a Pediatric Endocrinology healthcare provider based in Los Angeles, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/12/2019. The National Provider Identifier (NPI) number assigned to this provider is 1447819388.

According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Nancy Chang, NP has received a total of $24,559 in payments from pharmaceutical and medical device companies, with $627.46 received in 2024. These payments were reported across 11 transactions from 2 companies. The most common payment nature is "" ($10,661).

Practice Information

  • Specialty Pediatric Endocrinology
  • Location Los Angeles, CA
  • Active Since 06/12/2019
  • Last Updated 06/12/2019
  • Taxonomy Code 2080P0205X
  • Entity Type Individual
  • NPI Number 1447819388

Products in Payments

  • Rybelsus (Drug) $23,932
  • INTELLIS ADAPTIVESTIM (Device) $97.46

Data Sources

Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.

Pediatric Endocrinology Doctors in Los Angeles